![\"a](\"https:\/\/www.europesays.com\/dk\/wp-content\/uploads\/2026\/02\/ed662e75219c820a2c1683a9a2872045.jpeg\")
Image source: Getty Images. <\/p>\n
When Novo Nordisk introduced Ozempic to the world<\/a>, investors jumped on board, recognizing the significant impact this diabetes drug could have on patients seeking help with weight-loss. It began marketing a drug, Wegovy, specifically to help with weight loss. When Eli Lilly’s GLP-1 variation, Mounjaro (for diabetes) and Zepbound (for weight loss), proved more attractive to patients, Novo Nordisk’s stock tanked, while Eli Lilly’s rose.<\/p>\n There’s really nothing shocking in any of this. Wall Street operates like this all the time. Yet there are implications to consider when stocks move up and down in dramatic fashion.<\/p>\n One of the biggest considerations is valuation,<\/a> which is more art than science. But the effect of the different price moves here has been pretty clear.<\/p>\n Eli Lilly’s price-to-earnings ratio (P\/E) is a lofty 50, while Novo Nordisk’s is around 18. Lilly’s P\/E is currently below its five-year average of 55, but Novo Nordisk’s five-year average P\/E is 30. All in, the latter is cheaper on both an absolute basis and relative to its own history. Novo Nordisk is offering a generous 2.8% dividend yield versus a miserly 0.6% yield for Eli Lilly.<\/p>\n To be fair, you could argue that Novo Nordisk isn’t the leader in the GLP-1 space. That’s true, but it is still an innovative pharmaceutical company.<\/p>\n For example, it was the first to market with a GLP-1 pill. Given that consumers generally prefer pills over injections, it has a chance to regain some market share from Eli Lilly, which is working on a pill, too, so this isn’t a long-term benefit.<\/p>\n All this speaks to the competitive nature of the drug sector. Eli Lilly isn’t going to be on top forever. Notably, Pfizer (NYSE: PFE) is working on its own GLP-1 drug lineup, using acquisitions and partnerships in an effort to speed up its product development.<\/p>\n Which is why you might want to buy Novo Nordisk at a bargain price. However, the real key is that it makes more than just GLP-1 drugs.<\/p>\n It is also a leader in the diabetes space more generally. While GLP-1 drugs are beneficial for diabetics, the company’s historical strength is in the production and sale of insulin. The ongoing need for insulin creates repeat customers, which, in turn, makes this business a reliable cash flow generator.<\/p>\n In fact, the dividend payout ratio is a very comfortable 40% or so, thanks to the robust business hidden behind the GLP-1 story. That low a payout ratio suggests that the high yield here is very secure.<\/p>\n Novo Nordisk has leaped ahead on the innovation front with its GLP-1 pill, but that isn’t the big reason to like the stock. If you are a dividend investor or prefer to err on the side of value, the stock should look attractive to you right now. The innovation side of things will ebb and flow, but Novo Nordisk’s core diabetes business remains a solid foundation for both the dividend and the company’s long-term growth.<\/p>\n Before you buy stock in Novo Nordisk, consider this:<\/p>\n The Motley Fool Stock Advisor analyst team just identified what they believe are the\u00a010 best stocks<\/a> for investors to buy now\u2026 and Novo Nordisk wasn\u2019t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.<\/p>\n Consider when Netflix made this list on December 17, 2004… if you invested $1,000 at the time of our recommendation,\u00a0you\u2019d have $450,256!* Or when Nvidia made this list on April 15, 2005… if you invested $1,000 at the time of our recommendation, you\u2019d have $1,171,666!*<\/p>\n Now, it\u2019s worth noting\u00a0Stock Advisor\u2019s total average return is 942% \u2014 a market-crushing outperformance compared to 196% for the S&P 500.\u00a0Don’t miss the latest top 10 list, available with\u00a0Stock Advisor, and join an investing community built by individual investors for individual investors.<\/p>\n See the 10 stocks \u00bb<\/a><\/p>\n *Stock Advisor returns as of February 2, 2026. <\/p>\n Reuben Gregg Brewer<\/a> has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Pfizer. The Motley Fool recommends Novo Nordisk. The Motley Fool has a disclosure policy<\/a>.<\/p>\n<\/a> Data by <\/a>YCharts.<\/a> <\/p>\n